鉄欠乏性貧血治療市場レポート：2030年までの動向、予測、競争分析

鉄欠乏性貧血治療の動向と予測

世界の鉄欠乏性貧血治療市場は、2024年から2030年までのCAGRが5.3%で、2030年までに推定46億米ドルに達すると予想されています。この市場の主な促進要因は、食品からの鉄摂取不足と赤血球の過度の減少に起因する鉄欠乏性貧血の発生率の高さ、特に女性と子供に影響を与えること、女性人口の急増、女性の健康に対する意識の高まりです。世界の鉄欠乏性貧血治療市場の将来は、病院、診療所、在宅医療市場に機会があり、有望に見えます。

鉄欠乏性貧血治療市場に関する洞察

Lucintelは、組換えエリスロポエチン療法を受けている患者や、経口手段による鉄の吸収を妨げる慢性疾患に苦しむ患者の需要が高いため、非経口鉄療法が予測期間を通じて最大のセグメントであり続けると予測しています。

この市場において、病院は複雑な症例を処理する設備が整い、患者を管理するために必要な施設とスタッフを備えているため、今後も最大のセグメントとなるでしょう。

北米は、ヘルスケア費の急増、国民の鉄欠乏性貧血の有病率の増加、およびこの地域における主要な市場プレーヤーの存在により、予測期間を通じて最大の地域であり続けると予想されます。

よくある質問

Q1.市場規模は：

A1.世界の鉄欠乏性貧血治療市場は、2030年までに推定46億米ドルに達すると予想されています。

Q2.市場の成長予測は：

A2.世界の鉄欠乏性貧血治療市場は、2024年から2030年までCAGR 5.3%で成長すると予想されています。

Q3.市場の成長に影響を与える主な促進要因は：

A3.この市場の主な促進要因は、食品からの鉄摂取不足と赤血球の過度の減少に起因する鉄欠乏性貧血の発生率の高さ、特に女性と子供に影響を与えること、女性人口の急増、女性の健康に対する意識の高まりです。

Q4.市場の主要セグメントは：

A4.世界の鉄欠乏性貧血治療市場の将来は、病院、診療所、在宅医療市場に機会があり、有望に見えます。

Q5.市場の主要企業は：

A5.主要な鉄欠乏性貧血治療会社は次のとおりです。

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Q6.今後、最大となる市場セグメントは：

A6.Lucintelは、組換えエリスロポエチン療法を受けている患者や、経口手段による鉄の吸収を妨げる慢性疾患に苦しむ患者の需要が高いため、非経口鉄療法が予測期間を通じて最大のセグメントであり続けると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は：

A7.北米は、ヘルスケア費の急増、国民の鉄欠乏性貧血の有病率の増加、およびこの地域における主要な市場プレーヤーの存在により、予測期間を通じて最大の地域であり続けると予想されます。

Q8.レポートのカスタマイズは可能か：

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の鉄欠乏性貧血治療市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の鉄欠乏性貧血治療市場の動向（2018～2023年）と予測（2024～2030年）
• 治療法別の世界の鉄欠乏性貧血治療市場
  • 経口鉄療法
  • 非経口鉄療法
  • 赤血球輸血
• 最終用途別の世界の鉄欠乏性貧血治療市場
  • 病院
  • 診療所
  • 在宅医療

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界の鉄欠乏性貧血治療市場
• 北米の鉄欠乏性貧血治療市場
• 欧州の鉄欠乏性貧血治療市場
• アジア太平洋の鉄欠乏性貧血治療市場
• その他地域の鉄欠乏性貧血治療市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • 治療法別の世界の鉄欠乏性貧血治療市場の成長機会
  • 最終用途別の世界の鉄欠乏性貧血治療市場の成長機会
  • 地域別の世界の鉄欠乏性貧血治療市場の成長機会
• 世界の鉄欠乏性貧血治療市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の鉄欠乏性貧血治療市場の能力拡大
  • 世界の鉄欠乏性貧血治療市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Iron Deficiency Anemia Therapy Trends and Forecast

The future of the global iron deficiency anemia therapy market looks promising with opportunities in the hospital, clinic, and home healthcare markets. The global iron deficiency anemia therapy market is expected to reach an estimated $4.6 billion by 2030 with a CAGR of 5.3% from 2024 to 2030. The major drivers for this market are high incidence of iron deficiency anemia is attributed to insufficient iron intake from food and excessive loss of red blood cells, particularly affecting women and children, surge in female population, and growing awareness towards women health.

A more than 150-page report is developed to help in your business decisions.

Iron Deficiency Anemia Therapy by Segment

The study includes a forecast for the global iron deficiency anemia therapy by therapy type, end use, and region.

Iron Deficiency Anemia Therapy Market by Therapy Type [Shipment Analysis by Value from 2018 to 2030]:

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusion

Iron Deficiency Anemia Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Clinics
• Home Healthcare

Iron Deficiency Anemia Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Iron Deficiency Anemia Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies iron deficiency anemia therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the iron deficiency anemia therapy companies profiled in this report include-

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Iron Deficiency Anemia Therapy Market Insights

Lucintel forecasts that parenteral iron therapy will remain the largest segment over the forecast period due to high demand for patients receiving recombinant erythropoietin therapy or suffering from chronic diseases that hinder iron absorption through oral means.

Within this market, hospital will remain the largest segment as it is equipped to handle complex cases and has necessary facilities and staffs to manage patients.

North America will remain the largest region over the forecast period due to surge in healthcare spending, increasing prevalence of iron deficiency anemia among the population, and the presence of key market players in the region.

Features of the Global Iron Deficiency Anemia Therapy Market

Market Size Estimates: Iron deficiency anemia therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Iron deficiency anemia therapy market size by therapy type, end use, and region in terms of value ($B).

Regional Analysis: Iron deficiency anemia therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapy types, end uses, and regions for the iron deficiency anemia therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the iron deficiency anemia therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the iron deficiency anemia therapy market size?

Answer: The global iron deficiency anemia therapy market is expected to reach an estimated $4.6 billion by 2030.

Q2. What is the growth forecast for iron deficiency anemia therapy market?

Answer: The global iron deficiency anemia therapy market is expected to grow with a CAGR of 5.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the iron deficiency anemia therapy market?

Answer: The major drivers for this market are high incidence of iron deficiency anemia is attributed to insufficient iron intake from food and excessive loss of red blood cells, particularly affecting women and children, surge in female population, and growing awareness towards women health.

Q4. What are the major segments for iron deficiency anemia therapy market?

Answer: The future of the global iron deficiency anemia therapy market looks promising with opportunities in the hospital, clinic, and home healthcare markets.

Q5. Who are the key iron deficiency anemia therapy market companies?

Answer: Some of the key iron deficiency anemia therapy companies are as follows:

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Q6. Which iron deficiency anemia therapy market segment will be the largest in future?

Answer: Lucintel forecasts that parenteral iron therapy will remain the largest segment over the forecast period due to high demand for patients receiving recombinant erythropoietin therapy or suffering from chronic diseases that hinder iron absorption through oral means.

Q7. In iron deficiency anemia therapy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to surge in healthcare spending, increasing prevalence of iron deficiency anemia among the population, and the presence of key market players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the iron deficiency anemia therapy market by therapy type (oral iron therapy, parenteral iron therapy, and red blood cell transfusion), end use (hospitals, clinics, and home healthcare), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Iron Deficiency Anemia Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Iron Deficiency Anemia Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Iron Deficiency Anemia Therapy Market by Therapy Type
  • 3.3.1: Oral Iron Therapy
  • 3.3.2: Parenteral Iron Therapy
  • 3.3.3: Red Blood Cell Transfusion
• 3.4: Global Iron Deficiency Anemia Therapy Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Clinics
  • 3.4.3: Home Healthcare

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Iron Deficiency Anemia Therapy Market by Region
• 4.2: North American Iron Deficiency Anemia Therapy Market
  • 4.2.2: North American Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.3: European Iron Deficiency Anemia Therapy Market
  • 4.3.1: European Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.3.2: European Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.4: APAC Iron Deficiency Anemia Therapy Market
  • 4.4.1: APAC Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.4.2: APAC Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.5: ROW Iron Deficiency Anemia Therapy Market
  • 4.5.1: ROW Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.5.2: ROW Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by Therapy Type
  • 6.1.2: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by End Use
  • 6.1.3: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by Region
• 6.2: Emerging Trends in the Global Iron Deficiency Anemia Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Iron Deficiency Anemia Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Iron Deficiency Anemia Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbvie
• 7.2: Akebia Therapeutics
• 7.3: AMAG Pharmaceuticals
• 7.4: Daiichi Sankyo
• 7.5: Pharmacosmos
• 7.6: Sanofi
• 7.7: Johnson and Johnson
• 7.8: Fresenius
• 7.9: ViforPharma
• 7.10: Rockwell Medical